Mitoxantrone Hydrochloride Liposome Combined with Polatuzumab Vedotin and Dexamethasone (MPD) Is Highly Effective and Well Tolerated As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma
第一作者机构：[1]Beijing Tongren Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Liu Xin-di,Cong Jia,Yang Lei,et al.Mitoxantrone Hydrochloride Liposome Combined with Polatuzumab Vedotin and Dexamethasone (MPD) Is Highly Effective and Well Tolerated As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma[J].BLOOD.2024,144:6475-6476.doi:10.1182/blood-2024-209754.
APA：
Liu, Xin-di,Cong, Jia,Yang, Lei,Yang, Jing&Wang, Liang.(2024).Mitoxantrone Hydrochloride Liposome Combined with Polatuzumab Vedotin and Dexamethasone (MPD) Is Highly Effective and Well Tolerated As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma.BLOOD,144,
MLA：
Liu, Xin-di,et al."Mitoxantrone Hydrochloride Liposome Combined with Polatuzumab Vedotin and Dexamethasone (MPD) Is Highly Effective and Well Tolerated As Bridging Therapy before Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma".BLOOD 144.(2024):6475-6476
医学